{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:00:34Z","timestamp":1793851234110,"version":"4.6.1"},"reference-count":240,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The Billroth\u00a0IV consensus was developed during a\u00a0consensus meeting of the Austrian Society of Gastroenterology and Hepatology (\u00d6GGH) and the Austrian Society of Interventional Radiology (\u00d6GIR) held on the 26th\u00a0of November 2022 in Vienna.<\/jats:p><jats:p>Based on international recommendations and considering recent landmark studies, the Billroth\u00a0IV consensus provides guidance regarding the diagnosis and management of portal hypertension in advanced chronic liver disease.<\/jats:p>","DOI":"10.1007\/s00508-023-02229-w","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T09:03:30Z","timestamp":1687770210000},"page":"493-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth\u00a0IV)"],"prefix":"10.1007","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2330-0017","authenticated-orcid":false,"given":"Mattias","family":"Mandorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Cejna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Ferlitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Datz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilmann","family":"Gr\u00e4ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Graziadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gschwantler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hametner-Schreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Jachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Loizides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maieron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Reider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Sch\u00f6fl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Stadlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Tatscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ziachehabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"2229_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt\u00a0GH, Oxman\u00a0AD, Vist\u00a0GE, Kunz\u00a0R, Falck-Ytter\u00a0Y, Alonso-Coello\u00a0P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"2229_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis\u00a0R, Bosch\u00a0J, Garcia-Tsao\u00a0G, Reiberger\u00a0T, Ripoll\u00a0C, Baveno VII Faculty. Baveno VII\u2014renewing consensus in portal hypertension. J\u00a0Hepatol. 2022;76:959\u201374.","journal-title":"J Hepatol"},{"key":"2229_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/liv.12623","volume":"35","author":"P Schwabl","year":"2015","unstructured":"Schwabl\u00a0P, Bota\u00a0S, Salzl\u00a0P, Mandorfer\u00a0M, Payer\u00a0BA, Ferlitsch\u00a0A, et\u00a0al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int. 2015;35:381\u201390.","journal-title":"Liver Int"},{"key":"2229_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J\u00a0Hepatol. 2021;75:659\u201389.","journal-title":"J Hepatol"},{"key":"2229_CR5","volume-title":"EASL liver congress (TM) abstract # 2477: is elastography needed for diagnosing cACLD and stratifying CSPH risk?","author":"G Semmler","year":"2023","unstructured":"Semmler\u00a0G, Hartl\u00a0L, Jachs\u00a0M, Simbrunner\u00a0B, Hofer\u00a0BS, Balcar\u00a0L, et\u00a0al. EASL liver congress (TM) abstract # 2477: is elastography needed for diagnosing cACLD and stratifying CSPH risk? 2023."},{"key":"2229_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","volume":"69","author":"J Bosch","year":"2020","unstructured":"Bosch\u00a0J, Gracia-Sancho\u00a0J, Abraldes\u00a0JG. Cirrhosis as new indication for statins. Gut. 2020;69:953\u201362.","journal-title":"Gut"},{"key":"2229_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.dld.2019.01.020","volume":"51","author":"J Stift","year":"2019","unstructured":"Stift\u00a0J, Semmler\u00a0G, Walzel\u00a0C, Mandorfer\u00a0M, Schwarzer\u00a0R, Schwabl\u00a0P, et\u00a0al. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Dig Liver Dis. 2019;51:1144\u201351.","journal-title":"Dig Liver Dis"},{"key":"2229_CR8","doi-asserted-by":"publisher","DOI":"10.3791\/58819","author":"T Reiberger","year":"2020","unstructured":"Reiberger\u00a0T, Schwabl\u00a0P, Trauner\u00a0M, Peck-Radosavljevic\u00a0M, Mandorfer\u00a0M. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J\u00a0Vis Exp. 2020; https:\/\/doi.org\/10.3791\/58819.","journal-title":"J Vis Exp"},{"key":"2229_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1365-2036.2010.04484.x","volume":"32","author":"A Zipprich","year":"2010","unstructured":"Zipprich\u00a0A, Winkler\u00a0M, Seufferlein\u00a0T, Dollinger\u00a0MM. Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther. 2010;32:1351\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"2229_CR10","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/liv.12783","volume":"35","author":"A Ferlitsch","year":"2015","unstructured":"Ferlitsch\u00a0A, Bota\u00a0S, Paternostro\u00a0R, Reiberger\u00a0T, Mandorfer\u00a0M, Heinisch\u00a0B, et\u00a0al. Evaluation of a\u00a0new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. Liver Int. 2015;35:2115\u201320.","journal-title":"Liver Int"},{"key":"2229_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jvir.2011.08.003","volume":"22","author":"G Maleux","year":"2011","unstructured":"Maleux\u00a0G, Willems\u00a0E, Fieuws\u00a0S, Heye\u00a0S, Vaninbroukx\u00a0J, Laleman\u00a0W, et\u00a0al. Prospective study comparing different indirect methods to measure portal pressure. J\u00a0Vasc Interv Radiol. 2011;22:1553\u20138.","journal-title":"J Vasc Interv Radiol"},{"key":"2229_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/hep.20062","volume":"39","author":"RJ Groszmann","year":"2004","unstructured":"Groszmann\u00a0RJ, Wongcharatrawee\u00a0S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280\u20132.","journal-title":"Hepatology"},{"key":"2229_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.510290421","volume":"29","author":"AF Steinlauf","year":"1999","unstructured":"Steinlauf\u00a0AF, Garcia-Tsao\u00a0G, Zakko\u00a0MF, Dickey\u00a0K, Gupta\u00a0T, Groszmann\u00a0RJ. Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements. Hepatology. 1999;29:1070\u20133.","journal-title":"Hepatology"},{"key":"2229_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/liv.12229","volume":"34","author":"E Reverter","year":"2014","unstructured":"Reverter\u00a0E, Blasi\u00a0A, Abraldes\u00a0JG, Martinez-Palli\u00a0G, Seijo\u00a0S, Turon\u00a0F, et al. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2014;34:16\u201325.","journal-title":"Liver Int"},{"key":"2229_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12072-021-10261-z","volume":"16","author":"F Ebrahimi","year":"2022","unstructured":"Ebrahimi\u00a0F, Semela\u00a0D, Heim\u00a0M. Impact of propofol sedation on the diagnostic accuracy of hepatic venous pressure gradient measurements in patients with cirrhosis. Hepatol Int. 2022;16:817\u201323.","journal-title":"Hepatol Int"},{"key":"2229_CR16","doi-asserted-by":"publisher","first-page":"e0002","DOI":"10.1097\/HC9.0000000000000002","volume":"7","author":"H Zhang","year":"2023","unstructured":"Zhang\u00a0H, Yang\u00a0L, Yu\u00a0Z, Li\u00a0D, Li\u00a0L, Li\u00a0S, et\u00a0al. Impact of fentanyl analgesia on the accuracy of HVPG measurements in patients with cirrhosis: a\u00a0prospective, multicenter study. Hepatol Commun. 2023;7:e2.","journal-title":"Hepatol Commun"},{"key":"2229_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/liv.12522","volume":"35","author":"S Casu","year":"2015","unstructured":"Casu\u00a0S, Berzigotti\u00a0A, Abraldes\u00a0JG, Baringo\u00a0MA, Rocabert\u00a0L, Hernandez-Gea\u00a0V, et al. A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. Liver Int. 2015;35:695\u2013703.","journal-title":"Liver Int"},{"key":"2229_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/hep.1840090604","volume":"9","author":"S Gaiani","year":"1989","unstructured":"Gaiani\u00a0S, Bolondi\u00a0L, Bassi\u00a0LS, Santi\u00a0V, Zironi\u00a0G, Barbara\u00a0L. Effect of meal on portal hemodynamics in healthy humans and in patients with chronic liver disease. Hepatology. 1989;9:815\u20139.","journal-title":"Hepatology"},{"key":"2229_CR19","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jhep.2022.05.033","volume":"77","author":"A De Gottardi","year":"2022","unstructured":"De Gottardi\u00a0A, Sempoux\u00a0C, Berzigotti\u00a0A. Porto-sinusoidal vascular disorder. J\u00a0Hepatol. 2022;77:1124\u201335.","journal-title":"J Hepatol"},{"key":"2229_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jvir.2016.03.028","volume":"27","author":"M Rossle","year":"2016","unstructured":"Rossle\u00a0M, Blanke\u00a0P, Fritz\u00a0B, Schultheiss\u00a0M, Bettinger\u00a0D. Free hepatic vein pressure is not useful to calculate the portal pressure gradient in cirrhosis: a morphologic and hemodynamic study. J\u00a0Vasc Interv Radiol. 2016;27:1130\u20137.","journal-title":"J Vasc Interv Radiol"},{"key":"2229_CR21","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.28031","volume":"62","author":"G Silva-Junior","year":"2015","unstructured":"Silva-Junior\u00a0G, Baiges\u00a0A, Turon\u00a0F, Torres\u00a0F, Hernandez-Gea\u00a0V, Bosch\u00a0J, et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology. 2015;62:1584\u201392.","journal-title":"Hepatology"},{"key":"2229_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll\u00a0C, Groszmann\u00a0R, Garcia-Tsao\u00a0G, Grace\u00a0N, Burroughs\u00a0A, Planas\u00a0R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481\u20138.","journal-title":"Gastroenterology"},{"key":"2229_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.30885","volume":"71","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer\u00a0M, Kozbial\u00a0K, Schwabl\u00a0P, Chromy\u00a0D, Semmler\u00a0G, St\u00e4ttermayer\u00a0AF, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology. 2020;71:1023\u201336.","journal-title":"Hepatology"},{"key":"2229_CR24","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/bjs.7672","volume":"98","author":"S Stremitzer","year":"2011","unstructured":"Stremitzer\u00a0S, Tamandl\u00a0D, Kaczirek\u00a0K, Maresch\u00a0J, Abbasov\u00a0B, Payer\u00a0BA, et\u00a0al. Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Br J Surg. 2011;98:1752\u20138.","journal-title":"Br J Surg"},{"key":"2229_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig\u00a0M, Forner\u00a0A, Rimola\u00a0J, Ferrer-Fabrega\u00a0J, Burrel\u00a0M, Garcia-Criado\u00a0A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J\u00a0Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"2229_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jhep.2019.07.007","volume":"71","author":"E Reverter","year":"2019","unstructured":"Reverter\u00a0E, Cirera\u00a0I, Albillos\u00a0A, Debernardi-Venon\u00a0W, Abraldes\u00a0JG, Llop\u00a0E, et al. The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. J\u00a0Hepatol. 2019;71:942\u201350.","journal-title":"J Hepatol"},{"key":"2229_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s11901-019-00469-x","volume":"18","author":"M Mandorfer","year":"2019","unstructured":"Mandorfer\u00a0M, Hern\u00e1ndez-Gea\u00a0V, Reiberger\u00a0T, Garc\u00eda-Pag\u00e1n\u00a0JC. Hepatic venous pressure gradient response in non-selective beta-blocker treatment\u2014is it worth measuring? Curr Hepatology Rep. 2019;18:174\u201386.","journal-title":"Curr Hepatology Rep"},{"key":"2229_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.dld.2021.09.009","volume":"54","author":"R Paternostro","year":"2022","unstructured":"Paternostro\u00a0R, Becker\u00a0J, Hofer\u00a0BS, Panagl\u00a0V, Schiffke\u00a0H, Simbrunner\u00a0B, et al. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis. 2022;54:500\u20138.","journal-title":"Dig Liver Dis"},{"key":"2229_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","volume":"18","author":"L Turco","year":"2020","unstructured":"Turco\u00a0L, Villanueva\u00a0C, La Mura\u00a0V, Garcia-Pagan\u00a0JC, Reiberger\u00a0T, Genesca\u00a0J, et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis. Clin Gastroenterol Hepatol. 2020;18:313\u2013327.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva\u00a0C, Albillos\u00a0A, Genesca\u00a0J, Garcia-Pagan\u00a0JC, Calleja\u00a0JL, Aracil\u00a0C, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a\u00a0randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597\u2013608.","journal-title":"Lancet"},{"key":"2229_CR31","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/hep4.2021","volume":"6","author":"BS Hofer","year":"2022","unstructured":"Hofer\u00a0BS, Simbrunner\u00a0B, Bauer\u00a0DJM, Paternostro\u00a0R, Schwabl\u00a0P, Scheiner\u00a0B, et\u00a0al. Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. Hepatol Commun. 2022;6:2569\u201380.","journal-title":"Hepatol Commun"},{"key":"2229_CR32","doi-asserted-by":"publisher","first-page":"S619","DOI":"10.1016\/S0168-8278(20)31704-9","volume":"73","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer\u00a0M, Turon\u00a0F, Lens\u00a0S, Baiges\u00a0A, Ferrusquia\u00a0J, Magaz\u00a0M, et al. Sustained virologic response to direct-acting antivirals does affect the risk of portal vein thrombosis in patients with advanced chronic liver disease. J\u00a0Hepatol. 2020;73:S619\u2013S20.","journal-title":"J Hepatol"},{"key":"2229_CR33","doi-asserted-by":"publisher","first-page":"101811","DOI":"10.1016\/j.bpg.2022.101811","volume":"60\u201361","author":"W Laleman","year":"2022","unstructured":"Laleman\u00a0W, Vanderschueren\u00a0E, Van der Merwe\u00a0S, Chang\u00a0KJ. The use of endoscopic ultrasound in the diagnosis and management of portal hypertension. Best Pract Res Clin Gastroenterol. 2022;60\u201361:101811.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2229_CR34","doi-asserted-by":"publisher","first-page":"e0149230","DOI":"10.1371\/journal.pone.0149230","volume":"11","author":"S Hametner","year":"2016","unstructured":"Hametner\u00a0S, Ferlitsch\u00a0A, Ferlitsch\u00a0M, Etschmaier\u00a0A, Sch\u00f6fl\u00a0R, Ziachehabi\u00a0A, et al. The VITRO score (von Willebrand factor antigen\/thrombocyte ratio) as a\u00a0new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test. PLoS ONE. 2016;11:e149230.","journal-title":"PLoS ONE"},{"key":"2229_CR35","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.31462","volume":"73","author":"G Semmler","year":"2021","unstructured":"Semmler\u00a0G, Binter\u00a0T, Kozbial\u00a0K, Schwabl\u00a0P, Hametner-Schreil\u00a0S, Zanetto\u00a0A, et al. Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver disease. Hepatology. 2021;73:1275\u201389.","journal-title":"Hepatology"},{"key":"2229_CR36","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.cgh.2021.07.012","volume":"20","author":"M Jachs","year":"2022","unstructured":"Jachs\u00a0M, Hartl\u00a0L, Simbrunner\u00a0B, Bauer\u00a0D, Paternostro\u00a0R, Scheiner\u00a0B, et al. Decreasing von Willebrand factor levels upon nonselective beta blocker therapy indicate a\u00a0decreased risk of further decompensation, acute-on-chronic liver failure, and death. Clin Gastroenterol Hepatol. 2022;20:1362\u20131373.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/liv.12657","volume":"35","author":"PA Reuken","year":"2015","unstructured":"Reuken\u00a0PA, Kussmann\u00a0A, Kiehntopf\u00a0M, Budde\u00a0U, Stallmach\u00a0A, Claus\u00a0RA, et\u00a0al. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. Liver Int. 2015;35:37\u201345.","journal-title":"Liver Int"},{"key":"2229_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.09.032","author":"M Jachs","year":"2022","unstructured":"Jachs\u00a0M, Hartl\u00a0L, Simbrunner\u00a0B, Bauer\u00a0D, Paternostro\u00a0R, Scheiner\u00a0B, et\u00a0al. The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension. Clin Gastroenterol Hepatol. 2022; https:\/\/doi.org\/10.1016\/j.cgh.2022.09.032.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR39","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.14309\/ajg.0000000000001887","volume":"117","author":"E Dajti","year":"2022","unstructured":"Dajti\u00a0E, Ravaioli\u00a0F, Marasco\u00a0G, Alemanni\u00a0LV, Colecchia\u00a0L, Ferrarese\u00a0A, et\u00a0al. A combined Baveno VII and spleen stiffness algorithm to improve the noninvasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2022;117:1825\u201333.","journal-title":"Am J Gastroenterol"},{"key":"2229_CR40","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/j.cgh.2020.11.039","volume":"20","author":"K W\u00f6ran","year":"2022","unstructured":"W\u00f6ran\u00a0K, Semmler\u00a0G, Jachs\u00a0M, Simbrunner\u00a0B, Bauer\u00a0DJM, Binter\u00a0T, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension. Clin Gastroenterol Hepatol. 2022;20:e251\u2013e66.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR41","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/hep.31688","volume":"74","author":"L Elkrief","year":"2021","unstructured":"Elkrief\u00a0L, Lazareth\u00a0M, Chevret\u00a0S, Paradis\u00a0V, Magaz\u00a0M, Blaise\u00a0L, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Hepatology. 2021;74:364\u201378.","journal-title":"Hepatology"},{"key":"2229_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dld.2022.09.018","volume":"55","author":"J Ferreira-Silva","year":"2023","unstructured":"Ferreira-Silva\u00a0J, Gaspar\u00a0R, Liberal\u00a0R, Cardoso\u00a0H, Macedo\u00a0G. Splenic-hepatic elastography index is useful in differentiating between porto-sinusoidal vascular disease and cirrhosis in patients with portal hypertension. Dig Liver Dis. 2023;55:75\u201380.","journal-title":"Dig Liver Dis"},{"key":"2229_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","volume":"116","author":"M Pons","year":"2021","unstructured":"Pons\u00a0M, Augustin\u00a0S, Scheiner\u00a0B, Guillaume\u00a0M, Rosselli\u00a0M, Rodrigues\u00a0SG, et\u00a0al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2021;116:723\u201332.","journal-title":"Am J Gastroenterol"},{"key":"2229_CR44","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.jhep.2022.08.025","volume":"77","author":"G Semmler","year":"2022","unstructured":"Semmler\u00a0G, Lens\u00a0S, Meyer\u00a0EL, Baiges\u00a0A, Alvardo-Tapias\u00a0E, Llop\u00a0E, et al. Non-invasive tests for clinically significant portal hypertension after HCV cure. J\u00a0Hepatol. 2022;77:1573\u201385.","journal-title":"J Hepatol"},{"key":"2229_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00508-017-1262-3","volume":"129","author":"T Reiberger","year":"2017","unstructured":"Reiberger\u00a0T, P\u00fcsp\u00f6k\u00a0A, Schoder\u00a0M, Baumann-Durchschein\u00a0F, Bucsics\u00a0T, Datz\u00a0C, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr. 2017;129:135\u201358.","journal-title":"Wien Klin Wochenschr"},{"key":"2229_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00508-019-01593-w","volume":"132","author":"B Simbrunner","year":"2020","unstructured":"Simbrunner\u00a0B, Beer\u00a0A, W\u00f6ran\u00a0K, Schmitz\u00a0F, Primas\u00a0C, Wewalka\u00a0M, et\u00a0al. Portal hypertensive gastropathy is associated with iron deficiency anemia. Wien Klin Wochenschr. 2020;132:1\u201311.","journal-title":"Wien Klin Wochenschr"},{"key":"2229_CR47","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jhep.2013.10.008","volume":"60","author":"LA Smith","year":"2014","unstructured":"Smith\u00a0LA, Morris\u00a0AJ, Stanley\u00a0AJ. The use of hemospray in portal hypertensive bleeding; a\u00a0case series. J\u00a0Hepatol. 2014;60:457\u201360.","journal-title":"J Hepatol"},{"key":"2229_CR48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.gie.2021.08.017","volume":"94","author":"BP Mohan","year":"2021","unstructured":"Mohan\u00a0BP, Toy\u00a0G, Kassab\u00a0LL, Ponnada\u00a0S, Chandan\u00a0S, Parbhu\u00a0S, et al. Endoscopic band ligation in the treatment of gastric antral vascular ectasia: a\u00a0systematic review and meta-analysis. Gastrointest Endosc. 2021;94:1021\u20131029.e10.","journal-title":"Gastrointest Endosc"},{"key":"2229_CR49","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMoa044456","volume":"353","author":"RJ Groszmann","year":"2005","unstructured":"Groszmann\u00a0RJ, Garcia-Tsao\u00a0G, Bosch\u00a0J, Grace\u00a0ND, Burroughs\u00a0AK, Planas\u00a0R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N\u00a0Engl J Med. 2005;353:2254\u201361.","journal-title":"N Engl J Med"},{"key":"2229_CR50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hep.28264","volume":"63","author":"C Villanueva","year":"2016","unstructured":"Villanueva\u00a0C, Albillos\u00a0A, Genesca\u00a0J, Abraldes\u00a0JG, Calleja\u00a0JL, Aracil\u00a0C, et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016;63:197\u2013206.","journal-title":"Hepatology"},{"key":"2229_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/apt.12634","volume":"39","author":"E Sinagra","year":"2014","unstructured":"Sinagra\u00a0E, Perricone\u00a0G, D\u2019Amico\u00a0M, Tin\u00e8\u00a0F, D\u2019Amico\u00a0G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39:557\u201368.","journal-title":"Aliment Pharmacol Ther"},{"key":"2229_CR52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2013.10.018","volume":"146","author":"E Reverter","year":"2014","unstructured":"Reverter\u00a0E, Tandon\u00a0P, Augustin\u00a0S, Turon\u00a0F, Casu\u00a0S, Bastiampillai\u00a0R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146:412\u2013419.e3.","journal-title":"Gastroenterology"},{"key":"2229_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.gastro.2020.09.026","volume":"160","author":"O Nicoara-Farcau","year":"2021","unstructured":"Nicoara-Farcau\u00a0O, Han\u00a0G, Rudler\u00a0M, Angrisani\u00a0D, Monescillo\u00a0A, Torres\u00a0F, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a\u00a0meta-analysis of individual patient data. Gastroenterology. 2021;160:193\u2013205.e10.","journal-title":"Gastroenterology"},{"key":"2229_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1211801","volume":"368","author":"C Villanueva","year":"2013","unstructured":"Villanueva\u00a0C, Colomo\u00a0A, Bosch\u00a0A, Concepcion\u00a0M, Hernandez-Gea\u00a0V, Aracil\u00a0C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N\u00a0Engl J Med. 2013;368:11\u201321.","journal-title":"N Engl J Med"},{"key":"2229_CR55","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","volume":"76","author":"European Association for the Study of the Liver","year":"2022","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J\u00a0Hepatol. 2022;76:1151\u201384.","journal-title":"J Hepatol"},{"key":"2229_CR56","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/hep.27006","volume":"60","author":"YS Seo","year":"2014","unstructured":"Seo\u00a0YS, Park\u00a0SY, Kim\u00a0MY, Kim\u00a0JH, Park\u00a0JY, Yim\u00a0HJ, et\u00a0al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014;60:954\u201363.","journal-title":"Hepatology"},{"key":"2229_CR57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12664-018-0871-8","volume":"37","author":"SK Jha","year":"2018","unstructured":"Jha\u00a0SK, Mishra\u00a0M, Jha\u00a0A, Dayal\u00a0VM. Comparison of continuous versus intermittent infusions of terlipressin for the control of acute variceal bleeding in patients with portal hypertension: an open-label randomized controlled trial. Indian J Gastroenterol. 2018;37:313\u201320.","journal-title":"Indian J Gastroenterol"},{"key":"2229_CR58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12072-022-10416-6","volume":"17","author":"V Arora","year":"2023","unstructured":"Arora\u00a0V, Choudhary\u00a0SP, Maiwall\u00a0R, Vijayaraghavan\u00a0R, Jindal\u00a0A, Kumar\u00a0G, et al. Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding. Hepatol Int. 2023;17:131\u20138.","journal-title":"Hepatol Int"},{"key":"2229_CR59","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/hep.28360","volume":"63","author":"A Escorsell","year":"2016","unstructured":"Escorsell\u00a0A, Pavel\u00a0O, Cardenas\u00a0A, Morillas\u00a0R, Llop\u00a0E, Villanueva\u00a0C, et\u00a0al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: a multicenter randomized, controlled trial. Hepatology. 2016;63:1957\u201367.","journal-title":"Hepatology"},{"key":"2229_CR60","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/liv.13971","volume":"39","author":"N Pfisterer","year":"2019","unstructured":"Pfisterer\u00a0N, Riedl\u00a0F, Pachofszky\u00a0T, Gschwantler\u00a0M, Konig\u00a0K, Schuster\u00a0B, et al. Outcomes after placement of a\u00a0SX-ELLA oesophageal stent for refractory variceal bleeding\u2014a national multicentre study. Liver Int. 2019;39:290\u20138.","journal-title":"Liver Int"},{"key":"2229_CR61","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J\u00a0Hepatol. 2018;69:406\u201360.","journal-title":"J Hepatol"},{"key":"2229_CR62","unstructured":"Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a\u00a0distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 1437;1437:e1421\u20139."},{"key":"2229_CR63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin\u00a0SK, Choudhury\u00a0A, Sharma\u00a0MK, Maiwall\u00a0R, Al Mahtab\u00a0M, Rahman\u00a0S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353\u201390.","journal-title":"Hepatol Int"},{"key":"2229_CR64","doi-asserted-by":"publisher","first-page":"S632","DOI":"10.1016\/S0168-8278(22)01581-1","volume":"77","author":"M Jachs","year":"2022","unstructured":"Jachs\u00a0M, Hartl\u00a0L, Simbrunner\u00a0B, Bauer\u00a0DJM, Paternostro\u00a0R, Balcar\u00a0L, et\u00a0al. Carvedilol is associated with superior hemodynamic response and rebleeding rates in comparison to propranolol in secondary prophylaxis of variceal bleeding. J\u00a0Hepatol. 2022;77:S632\u2013S3.","journal-title":"J Hepatol"},{"key":"2229_CR65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jhep.2007.10.008","volume":"48","author":"JG Abraldes","year":"2008","unstructured":"Abraldes\u00a0JG, Villanueva\u00a0C, Ba\u00f1ares\u00a0R, Aracil\u00a0C, Catalina\u00a0MV, Garci\u00a0APJC, et\u00a0al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J\u00a0Hepatol. 2008;48:229\u201336.","journal-title":"J Hepatol"},{"key":"2229_CR66","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1080\/00365521.2016.1193218","volume":"51","author":"M Zhang","year":"2016","unstructured":"Zhang\u00a0M, Wang\u00a0G, Zhao\u00a0L, Wu\u00a0Z, Zhang\u00a0W, Zhang\u00a0C. Second prophylaxis of variceal bleeding in cirrhotic patients with a\u00a0high HVPG. Scand J Gastroenterol. 2016;51:1502\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"2229_CR67","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","volume":"77","author":"European Association for the Study of the Liver","year":"2022","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. J\u00a0Hepatol. 2022;77:807\u201324.","journal-title":"J Hepatol"},{"key":"2229_CR68","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.29146","volume":"66","author":"F Campagna","year":"2017","unstructured":"Campagna\u00a0F, Montagnese\u00a0S, Ridola\u00a0L, Senzolo\u00a0M, Schiff\u00a0S, De Rui\u00a0M, et\u00a0al. The animal naming test: an easy tool for the assessment of hepatic encephalopathy. Hepatology. 2017;66:198\u2013208.","journal-title":"Hepatology"},{"key":"2229_CR69","first-page":"665","volume-title":"Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie \u2013 Update 2021","author":"S Ewig","year":"2021","unstructured":"Ewig\u00a0S, Kolditz\u00a0M, Pletz\u00a0M, Altiner\u00a0A, Albrich\u00a0W, Dr\u00f6mann\u00a0D, et\u00a0al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie \u2013 Update 2021. 2021. pp.\u00a0665\u2013729."},{"key":"2229_CR70","first-page":"15","volume-title":"Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie \u2013 Update 2017","author":"K Dalhoff","year":"2018","unstructured":"Dalhoff\u00a0K, Abele-Horn\u00a0M, Andreas\u00a0S, Deja\u00a0M, Ewig\u00a0S, Gastmeier\u00a0P, et al. Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie \u2013 Update 2017. 2018. pp. 15\u201363."},{"key":"2229_CR71","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico\u00a0G, Garcia-Tsao\u00a0G, Pagliaro\u00a0L. Natural history and prognostic indicators of survival in cirrhosis: a\u00a0systematic review of 118\u00a0studies. J\u00a0Hepatol. 2006;44:217\u201331.","journal-title":"J Hepatol"},{"key":"2229_CR72","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","volume":"4","author":"R Planas","year":"2006","unstructured":"Planas\u00a0R, Montoliu\u00a0S, Balleste\u00a0B, Rivera\u00a0M, Miquel\u00a0M, Masnou\u00a0H, et\u00a0al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385\u201394.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR73","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/jhep.2003.50315","volume":"38","author":"KP Moore","year":"2003","unstructured":"Moore\u00a0KP, Wong\u00a0F, Gines\u00a0P, Bernardi\u00a0M, Ochs\u00a0A, Salerno\u00a0F, et\u00a0al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology. 2003;38:258\u201366.","journal-title":"Hepatology"},{"key":"2229_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","volume":"70","author":"GP Aithal","year":"2021","unstructured":"Aithal\u00a0GP, Palaniyappan\u00a0N, China\u00a0L, Harmala\u00a0S, Macken\u00a0L, Ryan\u00a0JM, et\u00a0al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70:9\u201329.","journal-title":"Gut"},{"key":"2229_CR75","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1001\/archinte.1986.00360230201029","volume":"146","author":"BA Runyon","year":"1986","unstructured":"Runyon\u00a0BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med. 1986;146:2259\u201361.","journal-title":"Arch Intern Med"},{"key":"2229_CR76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/0003-4819-117-3-215","volume":"117","author":"BA Runyon","year":"1992","unstructured":"Runyon\u00a0BA, Montano\u00a0AA, Akriviadis\u00a0EA, Antillon\u00a0MR, Irving\u00a0MA, McHutchison\u00a0JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215\u201320.","journal-title":"Ann Intern Med"},{"key":"2229_CR77","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/BF00210228","volume":"70","author":"HU Lautz","year":"1992","unstructured":"Lautz\u00a0HU, Selberg\u00a0O, Korber\u00a0J, Burger\u00a0M, Muller\u00a0MJ. Protein-calorie malnutrition in liver cirrhosis. Clin Investig. 1992;70:478\u201386.","journal-title":"Clin Investig"},{"key":"2229_CR78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cld.2011.12.009","volume":"16","author":"P Periyalwar","year":"2012","unstructured":"Periyalwar\u00a0P, Dasarathy\u00a0S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis. 2012;16:95\u2013131.","journal-title":"Clin Liver Dis"},{"key":"2229_CR79","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/liv.13750","volume":"38","author":"J Haberl","year":"2018","unstructured":"Haberl\u00a0J, Zollner\u00a0G, Fickert\u00a0P, Stadlbauer\u00a0V. To salt or not to salt?-That is the question in cirrhosis. Liver Int. 2018;38:1148\u201359.","journal-title":"Liver Int"},{"key":"2229_CR80","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","volume":"39","author":"J Santos","year":"2003","unstructured":"Santos\u00a0J, Planas\u00a0R, Pardo\u00a0A, Durandez\u00a0R, Cabre\u00a0E, Morillas\u00a0RM, et\u00a0al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J\u00a0Hepatol. 2003;39:187\u201392.","journal-title":"J Hepatol"},{"key":"2229_CR81","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/gut.2008.176495","volume":"59","author":"P Angeli","year":"2010","unstructured":"Angeli\u00a0P, Fasolato\u00a0S, Mazza\u00a0E, Okolicsanyi\u00a0L, Maresio\u00a0G, Velo\u00a0E, et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut. 2010;59:98\u2013104.","journal-title":"Gut"},{"key":"2229_CR82","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/0016-5085(87)90616-0","volume":"92","author":"G Daskalopoulos","year":"1987","unstructured":"Daskalopoulos\u00a0G, Laffi\u00a0G, Morgan\u00a0T, Pinzani\u00a0M, Harley\u00a0H, Reynolds\u00a0T, et\u00a0al. Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. Gastroenterology. 1987;92:1859\u201363.","journal-title":"Gastroenterology"},{"key":"2229_CR83","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/MEG.0000000000001678","volume":"32","author":"R Sehgal","year":"2020","unstructured":"Sehgal\u00a0R, Singh\u00a0H, Singh\u00a0IP. Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver. Eur J Gastroenterol Hepatol. 2020;32:535\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR84","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0168-8278(05)80217-X","volume":"17","author":"AL Gerbes","year":"1993","unstructured":"Gerbes\u00a0AL, Bertheau-Reitha\u00a0U, Falkner\u00a0C, Jungst\u00a0D, Paumgartner\u00a0G. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. J\u00a0Hepatol. 1993;17:353\u20138.","journal-title":"J Hepatol"},{"key":"2229_CR85","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","volume":"61","author":"F Wong","year":"2012","unstructured":"Wong\u00a0F, Watson\u00a0H, Gerbes\u00a0A, Vilstrup\u00a0H, Badalamenti\u00a0S, Bernardi\u00a0M, et\u00a0al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61:108\u201316.","journal-title":"Gut"},{"key":"2229_CR86","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/hep.24786","volume":"55","author":"M Bernardi","year":"2012","unstructured":"Bernardi\u00a0M, Caraceni\u00a0P, Navickis\u00a0RJ, Wilkes\u00a0MM. Albumin infusion in patients undergoing large-volume paracentesis: a\u00a0meta-analysis of randomized trials. Hepatology. 2012;55:1172\u201381.","journal-title":"Hepatology"},{"key":"2229_CR87","first-page":"394","volume":"92","author":"KM Peltekian","year":"1997","unstructured":"Peltekian\u00a0KM, Wong\u00a0F, Liu\u00a0PP, Logan\u00a0AG, Sherman\u00a0M, Blendis\u00a0LM. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol. 1997;92:394\u20139.","journal-title":"Am J Gastroenterol"},{"key":"2229_CR88","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/gutjnl-2019-318843","volume":"69","author":"M Bernardi","year":"2020","unstructured":"Bernardi\u00a0M, Angeli\u00a0P, Claria\u00a0J, Moreau\u00a0R, Gines\u00a0P, Jalan\u00a0R, et\u00a0al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69:1127\u201338.","journal-title":"Gut"},{"key":"2229_CR89","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0016-5085(79)90268-3","volume":"77","author":"TD Boyer","year":"1979","unstructured":"Boyer\u00a0TD, Zia\u00a0P, Reynolds\u00a0TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 1979;77:215\u201322.","journal-title":"Gastroenterology"},{"key":"2229_CR90","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0016-5085(85)80088-3","volume":"88","author":"EA Pariente","year":"1985","unstructured":"Pariente\u00a0EA, Bataille\u00a0C, Bercoff\u00a0E, Lebrec\u00a0D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology. 1985;88:1255\u20139.","journal-title":"Gastroenterology"},{"key":"2229_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0016-5085(82)90129-9","volume":"82","author":"J Cabrera","year":"1982","unstructured":"Cabrera\u00a0J, Arroyo\u00a0V, Ballesta\u00a0AM, Rimola\u00a0A, Gual\u00a0J, Elena\u00a0M, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2\u2011microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology. 1982;82:97\u2013105.","journal-title":"Gastroenterology"},{"key":"2229_CR92","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cgh.2014.07.060","volume":"13","author":"JG O\u2019Leary","year":"2015","unstructured":"O\u2019Leary\u00a0JG, Reddy\u00a0KR, Wong\u00a0F, Kamath\u00a0PS, Patton\u00a0HM, Biggins\u00a0SW, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13:753\u2013759.e1\u20132.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR93","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/gutjnl-2016-312129","volume":"65","author":"B Njei","year":"2016","unstructured":"Njei\u00a0B, McCarty\u00a0TR, Garcia-Tsao\u00a0G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut. 2016;65:1393\u20134.","journal-title":"Gut"},{"key":"2229_CR94","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","volume":"66","author":"T Reiberger","year":"2017","unstructured":"Reiberger\u00a0T, Mandorfer\u00a0M. Beta adrenergic blockade and decompensated cirrhosis. J\u00a0Hepatol. 2017;66:849\u201359.","journal-title":"J Hepatol"},{"key":"2229_CR95","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/liv.14040","volume":"39","author":"RJ Wong","year":"2019","unstructured":"Wong\u00a0RJ, Robinson\u00a0A, Ginzberg\u00a0D, Gomes\u00a0C, Liu\u00a0B, Bhuket\u00a0T. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: a meta-analysis. Liver Int. 2019;39:1080\u20138.","journal-title":"Liver Int"},{"key":"2229_CR96","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","volume":"69","author":"E Sola","year":"2018","unstructured":"Sola\u00a0E, Sole\u00a0C, Simon-Talero\u00a0M, Martin-Llahi\u00a0M, Castellote\u00a0J, Garcia-Martinez\u00a0R, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J\u00a0Hepatol. 2018;69:1250\u20139.","journal-title":"J Hepatol"},{"key":"2229_CR97","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jhep.2022.03.005","volume":"76","author":"P Caraceni","year":"2022","unstructured":"Caraceni\u00a0P, O\u2019Brien\u00a0A, Gines\u00a0P. Long-term albumin treatment in patients with cirrhosis and ascites. J\u00a0Hepatol. 2022;76:1306\u201317.","journal-title":"J Hepatol"},{"key":"2229_CR98","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","volume":"152","author":"C Bureau","year":"2017","unstructured":"Bureau\u00a0C, Thabut\u00a0D, Oberti\u00a0F, Dharancy\u00a0S, Carbonell\u00a0N, Bouvier\u00a0A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157\u201363.","journal-title":"Gastroenterology"},{"key":"2229_CR99","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1478-3231.2004.0991.x","volume":"24","author":"R Moreau","year":"2004","unstructured":"Moreau\u00a0R, Delegue\u00a0P, Pessione\u00a0F, Hillaire\u00a0S, Durand\u00a0F, Lebrec\u00a0D, et\u00a0al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 2004;24:457\u201364.","journal-title":"Liver Int"},{"key":"2229_CR100","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1056\/NEJMra035021","volume":"350","author":"P Gines","year":"2004","unstructured":"Gines\u00a0P, Cardenas\u00a0A, Arroyo\u00a0V, Rodes\u00a0J. Management of cirrhosis and ascites. N\u00a0Engl J Med. 2004;350:1646\u201354.","journal-title":"N Engl J Med"},{"key":"2229_CR101","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.3748\/wjg.15.3631","volume":"15","author":"MA El-Bokl","year":"2009","unstructured":"El-Bokl\u00a0MA, Senousy\u00a0BE, El-Karmouty\u00a0KZ, Mohammed\u00a0IE, Mohammed\u00a0SM, Shabana\u00a0SS, et al. Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites. World J Gastroenterol. 2009;15:3631\u20135.","journal-title":"World J Gastroenterol"},{"key":"2229_CR102","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","volume":"53","author":"European Association for the Study of the Liver","year":"2010","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J\u00a0Hepatol. 2010;53:397\u2013417.","journal-title":"J Hepatol"},{"key":"2229_CR103","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","volume":"133","author":"F Salerno","year":"2007","unstructured":"Salerno\u00a0F, Camma\u00a0C, Enea\u00a0M, Rossle\u00a0M, Wong\u00a0F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a\u00a0meta-analysis of individual patient data. Gastroenterology. 2007;133:825\u201334.","journal-title":"Gastroenterology"},{"key":"2229_CR104","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.crad.2015.02.002","volume":"70","author":"RC Gaba","year":"2015","unstructured":"Gaba\u00a0RC, Parvinian\u00a0A, Casadaban\u00a0LC, Couture\u00a0PM, Zivin\u00a0SP, Lakhoo\u00a0J, et al. Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a\u00a0single institution case-control propensity score analysis. Clin Radiol. 2015;70:e51\u20137.","journal-title":"Clin Radiol"},{"key":"2229_CR105","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cgh.2015.06.042","volume":"14","author":"K Berry","year":"2016","unstructured":"Berry\u00a0K, Lerrigo\u00a0R, Liou\u00a0IW, Ioannou\u00a0GN. Association between transjugular intrahepatic portosystemic shunt and survival in patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14:118\u201323.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR106","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3748\/wjg.v20.i10.2704","volume":"20","author":"M Bai","year":"2014","unstructured":"Bai\u00a0M, Qi\u00a0XS, Yang\u00a0ZP, Yang\u00a0M, Fan\u00a0DM, Han\u00a0GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014;20:2704\u201314.","journal-title":"World J Gastroenterol"},{"key":"2229_CR107","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.cgh.2019.03.042","volume":"17","author":"J Trebicka","year":"2019","unstructured":"Trebicka\u00a0J, Bastgen\u00a0D, Byrtus\u00a0J, Praktiknjo\u00a0M, Terstiegen\u00a0S, Meyer\u00a0C, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival. Clin Gastroenterol Hepatol. 2019;17:2793\u20132799.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR108","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jgh.12725","volume":"30","author":"HK Tan","year":"2015","unstructured":"Tan\u00a0HK, James\u00a0PD, Sniderman\u00a0KW, Wong\u00a0F. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. J\u00a0Gastroenterol Hepatol. 2015;30:389\u201395.","journal-title":"J Gastroenterol Hepatol"},{"key":"2229_CR109","doi-asserted-by":"publisher","first-page":"100264","DOI":"10.1016\/j.jhepr.2021.100264","volume":"3","author":"M Praktiknjo","year":"2021","unstructured":"Praktiknjo\u00a0M, Abu-Omar\u00a0J, Chang\u00a0J, Thomas\u00a0D, Jansen\u00a0C, Kupczyk\u00a0P, et al. Controlled underdilation using novel VIATORR(R) controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep. 2021;3:100264.","journal-title":"JHEP Rep"},{"key":"2229_CR110","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jhep.2012.12.020","volume":"58","author":"P Bellot","year":"2013","unstructured":"Bellot\u00a0P, Welker\u00a0MW, Soriano\u00a0G, von Schaewen\u00a0M, Appenrodt\u00a0B, Wiest\u00a0R, et al. Automated low flow pump system for the treatment of refractory ascites: a\u00a0multi-center safety and efficacy study. J\u00a0Hepatol. 2013;58:922\u20137.","journal-title":"J Hepatol"},{"key":"2229_CR111","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2017.06.010","volume":"67","author":"C Bureau","year":"2017","unstructured":"Bureau\u00a0C, Adebayo\u00a0D, Chalret de Rieu\u00a0M, Elkrief\u00a0L, Valla\u00a0D, Peck-Radosavljevic\u00a0M, et al. Alfapump(R) system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study. J\u00a0Hepatol. 2017;67:940\u20139.","journal-title":"J Hepatol"},{"key":"2229_CR112","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/1756283X16684688","volume":"10","author":"G Stirnimann","year":"2017","unstructured":"Stirnimann\u00a0G, Banz\u00a0V, Storni\u00a0F, De Gottardi\u00a0A. Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites. Therap Adv Gastroenterol. 2017;10:283\u201392.","journal-title":"Therap Adv Gastroenterol"},{"key":"2229_CR113","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/apt.17066","volume":"56","author":"TL Tergast","year":"2022","unstructured":"Tergast\u00a0TL, Griemsmann\u00a0M, Stockhoff\u00a0L, Heidrich\u00a0B, Schirmer\u00a0H, Lenzen\u00a0H, et al. Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. Aliment Pharmacol Ther. 2022;56:529\u201339.","journal-title":"Aliment Pharmacol Ther"},{"key":"2229_CR114","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/MD.0000000000000025","volume":"93","author":"R Badillo","year":"2014","unstructured":"Badillo\u00a0R, Rockey\u00a0DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77\u00a0patients and review of the literature. Medicine. 2014;93:135\u201342.","journal-title":"Medicine"},{"key":"2229_CR115","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31434","volume":"72","author":"BA Banini","year":"2020","unstructured":"Banini\u00a0BA, Alwatari\u00a0Y, Stovall\u00a0M, Ogden\u00a0N, Gershman\u00a0E, Shah\u00a0RD, et al. Multidisciplinary management of hepatic hydrothorax in 2020: an evidence-based review and guidance. Hepatology. 2020;72:1851\u201363.","journal-title":"Hepatology"},{"key":"2229_CR116","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000346996","volume":"86","author":"A Singh","year":"2013","unstructured":"Singh\u00a0A, Bajwa\u00a0A, Shujaat\u00a0A. Evidence-based review of the management of hepatic hydrothorax. Respiration. 2013;86:155\u201373.","journal-title":"Respiration"},{"key":"2229_CR117","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1378\/chest.126.1.142","volume":"126","author":"LU Liu","year":"2004","unstructured":"Liu\u00a0LU, Haddadin\u00a0HA, Bodian\u00a0CA, Sigal\u00a0SH, Korman\u00a0JD, Bodenheimer\u00a0HC Jr., et\u00a0al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest. 2004;126:142\u20138.","journal-title":"Chest"},{"key":"2229_CR118","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s12072-009-9136-z","volume":"3","author":"ES Orman","year":"2009","unstructured":"Orman\u00a0ES, Lok\u00a0AS. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int. 2009;3:582\u20136.","journal-title":"Hepatol Int"},{"key":"2229_CR119","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.4254\/wjh.v7.i13.1797","volume":"7","author":"IC Ditah","year":"2015","unstructured":"Ditah\u00a0IC, Al Bawardy\u00a0BF, Saberi\u00a0B, Ditah\u00a0C, Kamath\u00a0PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: a systematic review and cumulative meta-analysis. World J Hepatol. 2015;7:1797\u2013806.","journal-title":"World J Hepatol"},{"key":"2229_CR120","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00042737-200105000-00011","volume":"13","author":"V Siegerstetter","year":"2001","unstructured":"Siegerstetter\u00a0V, Deibert\u00a0P, Ochs\u00a0A, Olschewski\u00a0M, Blum\u00a0HE, Rossle\u00a0M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40\u00a0patients. Eur J Gastroenterol Hepatol. 2001;13:529\u201334.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR121","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1432-2277.2005.00116.x","volume":"18","author":"X Xiol","year":"2005","unstructured":"Xiol\u00a0X, Tremosa\u00a0G, Castellote\u00a0J, Gornals\u00a0J, Lama\u00a0C, Lopez\u00a0C, et\u00a0al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int. 2005;18:672\u20135.","journal-title":"Transpl Int"},{"key":"2229_CR122","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.chest.2018.08.1034","volume":"155","author":"S Shojaee","year":"2019","unstructured":"Shojaee\u00a0S, Rahman\u00a0N, Haas\u00a0K, Kern\u00a0R, Leise\u00a0M, Alnijoumi\u00a0M, et\u00a0al. Indwelling tunneled pleural catheters for refractory hepatic hydrothorax in patients with cirrhosis: a multicenter study. Chest. 2019;155:546\u201353.","journal-title":"Chest"},{"key":"2229_CR123","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1007\/s10620-016-4260-9","volume":"61","author":"F Hou","year":"2016","unstructured":"Hou\u00a0F, Qi\u00a0X, Guo\u00a0X. Effectiveness and safety of pleurodesis for hepatic hydrothorax: a systematic review and meta-analysis. Dig Dis Sci. 2016;61:3321\u201334.","journal-title":"Dig Dis Sci"},{"key":"2229_CR124","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.athoracsur.2015.11.023","volume":"101","author":"PM Huang","year":"2016","unstructured":"Huang\u00a0PM, Kuo\u00a0SW, Chen\u00a0JS, Lee\u00a0JM. Thoracoscopic mesh repair of diaphragmatic defects in hepatic hydrothorax: a 10-year experience. Ann Thorac Surg. 2016;101:1921\u20137.","journal-title":"Ann Thorac Surg"},{"key":"2229_CR125","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/ajg.2014.212","volume":"109","author":"JJ Kim","year":"2014","unstructured":"Kim\u00a0JJ, Tsukamoto\u00a0MM, Mathur\u00a0AK, Ghomri\u00a0YM, Hou\u00a0LA, Sheibani\u00a0S, et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol. 2014;109:1436\u201342.","journal-title":"Am J Gastroenterol"},{"key":"2229_CR126","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/hep.27941","volume":"63","author":"S Piano","year":"2016","unstructured":"Piano\u00a0S, Fasolato\u00a0S, Salinas\u00a0F, Romano\u00a0A, Tonon\u00a0M, Morando\u00a0F, et\u00a0al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a\u00a0randomized, controlled clinical trial. Hepatology. 2016;63:1299\u2013309.","journal-title":"Hepatology"},{"key":"2229_CR127","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","volume":"53","author":"European Association for the Study of the Liver","year":"2010","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J\u00a0Hepatol. 2010;53:397\u2013417.","journal-title":"J Hepatol"},{"key":"2229_CR128","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"341","author":"P Sort","year":"1999","unstructured":"Sort\u00a0P, Navasa\u00a0M, Arroyo\u00a0V, Aldeguer\u00a0X, Planas\u00a0R, Ruiz-del-Arbol\u00a0L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N\u00a0Engl J Med. 1999;341:403\u20139.","journal-title":"N Engl J Med"},{"key":"2229_CR129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.dld.2016.09.013","volume":"49","author":"M Mandorfer","year":"2017","unstructured":"Mandorfer\u00a0M, Reiberger\u00a0T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49:3\u201310.","journal-title":"Dig Liver Dis"},{"key":"2229_CR130","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cld.2021.01.004","volume":"25","author":"M Jachs","year":"2021","unstructured":"Jachs\u00a0M, Reiberger\u00a0T. Prevention of variceal bleeding and rebleeding by nonselective beta-blockers: a tailored approach. Clin Liver Dis. 2021;25:311\u201326.","journal-title":"Clin Liver Dis"},{"key":"2229_CR131","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/hep.1840090313","volume":"9","author":"TL Fong","year":"1989","unstructured":"Fong\u00a0TL, Akriviadis\u00a0EA, Runyon\u00a0BA, Reynolds\u00a0TB. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology. 1989;9:423\u20136.","journal-title":"Hepatology"},{"key":"2229_CR132","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jhep.2016.01.039","volume":"64","author":"T Bucsics","year":"2016","unstructured":"Bucsics\u00a0T, Schwabl\u00a0P, Mandorfer\u00a0M, Peck-Radosavljevic\u00a0M. Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). J\u00a0Hepatol. 2016;64:1452\u20134.","journal-title":"J Hepatol"},{"key":"2229_CR133","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","volume":"133","author":"J Fern\u00e1ndez","year":"2007","unstructured":"Fern\u00e1ndez\u00a0J, Navasa\u00a0M, Planas\u00a0R, Montoliu\u00a0S, Monfort\u00a0D, Soriano\u00a0G, et\u00a0al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818\u201324.","journal-title":"Gastroenterology"},{"key":"2229_CR134","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/hep.28330","volume":"63","author":"J Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez\u00a0J, Tandon\u00a0P, Mensa\u00a0J, Garcia-Tsao\u00a0G. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology. 2016;63:2019\u201331.","journal-title":"Hepatology"},{"key":"2229_CR135","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/hep.1840120416","volume":"12","author":"P Gin\u00e9s","year":"1990","unstructured":"Gin\u00e9s\u00a0P, Rimola\u00a0A, Planas\u00a0R, Vargas\u00a0V, Marco\u00a0F, Almela\u00a0M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a\u00a0double-blind, placebo-controlled trial. Hepatology. 1990;12:716\u201324.","journal-title":"Hepatology"},{"key":"2229_CR136","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/cid\/ciz540","volume":"70","author":"MM M\u00fccke","year":"2020","unstructured":"M\u00fccke MM, Mayer A, Kessel J, M\u00fccke VT, Bon D, Schwarzkopf K et al. Quinolone and Multidrug Resistance Predicts Failure of Antibiotic Prophylaxis of Spontaneous Bacterial Peritonitis. Clin Infect Dis 2020;70:1916\u201324.","journal-title":"Clin Infect Dis"},{"key":"2229_CR137","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12072-015-9688-z","volume":"10","author":"M Assem","year":"2016","unstructured":"Assem\u00a0M, Elsabaawy\u00a0M, Abdelrashed\u00a0M, Elemam\u00a0S, Khodeer\u00a0S, Hamed\u00a0W, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a\u00a0prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;10:377\u201385.","journal-title":"Hepatol Int"},{"key":"2229_CR138","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/MEG.0000000000000724","volume":"28","author":"A Elfert","year":"2016","unstructured":"Elfert\u00a0A, Abo Ali\u00a0L, Soliman\u00a0S, Ibrahim\u00a0S, Abd-Elsalam\u00a0S. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2016;28:1450\u20134.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR139","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/MCG.0b013e3182506dbb","volume":"46","author":"MA Hanouneh","year":"2012","unstructured":"Hanouneh\u00a0MA, Hanouneh\u00a0IA, Hashash\u00a0JG, Law\u00a0R, Esfeh\u00a0JM, Lopez\u00a0R, et\u00a0al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J\u00a0Clin Gastroenterol. 2012;46:709\u201315.","journal-title":"J Clin Gastroenterol"},{"key":"2229_CR140","doi-asserted-by":"publisher","first-page":"e93909","DOI":"10.1371\/journal.pone.0093909","volume":"9","author":"P Lutz","year":"2014","unstructured":"Lutz\u00a0P, Parcina\u00a0M, Bekeredjian-Ding\u00a0I, Nischalke\u00a0HD, Nattermann\u00a0J, Sauerbruch\u00a0T, et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One. 2014;9:e93909.","journal-title":"PLoS One"},{"key":"2229_CR141","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jceh.2021.08.010","volume":"12","author":"DL Praharaj","year":"2022","unstructured":"Praharaj\u00a0DL, Premkumar\u00a0M, Roy\u00a0A, Verma\u00a0N, Taneja\u00a0S, Duseja\u00a0A, et\u00a0al. Rifaximin vs. norfloxacin for spontaneous bacterial peritonitis prophylaxis: a randomized controlled trial. J\u00a0Clin Exp Hepatol. 2022;12:336\u201342.","journal-title":"J Clin Exp Hepatol"},{"key":"2229_CR142","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1097\/MEG.0000000000000448","volume":"27","author":"MA Khan","year":"2015","unstructured":"Khan\u00a0MA, Kamal\u00a0S, Khan\u00a0S, Lee\u00a0WM, Howden\u00a0CW. Systematic review and meta-analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2015;27:1327\u201336.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR143","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14740\/gr1545","volume":"15","author":"L Dahabra","year":"2022","unstructured":"Dahabra\u00a0L, Kreidieh\u00a0M, Abureesh\u00a0M, Abou Yassine\u00a0A, Deeb\u00a0L. Proton pump inhibitors use and increased risk of spontaneous bacterial peritonitis in cirrhotic patients: a retrospective cohort analysis. Gastroenterology Res. 2022;15:180\u20137.","journal-title":"Gastroenterology Res"},{"key":"2229_CR144","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo\u00a0V, Gines\u00a0P, Gerbes\u00a0AL, Dudley\u00a0FJ, Gentilini\u00a0P, Laffi\u00a0G, et\u00a0al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International ascites club. Hepatology. 1996;23:164\u201376.","journal-title":"Hepatology"},{"key":"2229_CR145","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1053\/j.gastro.2013.08.051","volume":"145","author":"F Wong","year":"2013","unstructured":"Wong\u00a0F, O\u2019Leary\u00a0JG, Reddy\u00a0KR, Patton\u00a0H, Kamath\u00a0PS, Fallon\u00a0MB, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology. 2013;145:1280\u20131288.e1.","journal-title":"Gastroenterology"},{"key":"2229_CR146","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nrgastro.2012.96","volume":"9","author":"F Wong","year":"2012","unstructured":"Wong\u00a0F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol. 2012;9:382\u201391.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2229_CR147","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000444553","volume":"34","author":"AL Gerbes","year":"2016","unstructured":"Gerbes\u00a0AL. Liver cirrhosis and kidney. Dig Dis. 2016;34:387\u201390.","journal-title":"Dig Dis"},{"key":"2229_CR148","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","volume":"74","author":"SW Biggins","year":"2021","unstructured":"Biggins\u00a0SW, Angeli\u00a0P, Garcia-Tsao\u00a0G, Gines\u00a0P, Ling\u00a0SC, Nadim\u00a0MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;74:1014\u201348.","journal-title":"Hepatology"},{"key":"2229_CR149","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/ki.2013.78","volume":"84","author":"CM van Slambrouck","year":"2013","unstructured":"van Slambrouck\u00a0CM, Salem\u00a0F, Meehan\u00a0SM, Chang\u00a0A. Bile cast nephropathy is a\u00a0common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013;84:192\u20137.","journal-title":"Kidney Int"},{"key":"2229_CR150","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.bbadis.2017.08.028","volume":"1864","author":"E Krones","year":"2018","unstructured":"Krones\u00a0E, Pollheimer\u00a0MJ, Rosenkranz\u00a0AR, Fickert\u00a0P. Cholemic nephropathy\u2014historical notes and novel perspectives. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1356\u201366.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2229_CR151","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.ajkd.2014.05.010","volume":"64","author":"RL Luciano","year":"2014","unstructured":"Luciano\u00a0RL, Castano\u00a0E, Moeckel\u00a0G, Perazella\u00a0MA. Bile acid nephropathy in a\u00a0bodybuilder abusing an anabolic androgenic steroid. Am J Kidney Dis. 2014;64:473\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2229_CR152","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1111\/liv.15413","volume":"42","author":"R Maiwall","year":"2022","unstructured":"Maiwall\u00a0R, Rastogi\u00a0A, Pasupuleti\u00a0SSR, Hidam\u00a0AK, Singh\u00a0M, Kadyan\u00a0S, et al. Natural history, spectrum and outcome of stage 3 AKI in patients with acute-on-chronic liver failure. Liver Int. 2022;42(12):2800\u201314. https:\/\/doi.org\/10.1111\/liv.15413.","journal-title":"Liver Int"},{"key":"2229_CR153","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","volume":"71","author":"P Angeli","year":"2019","unstructured":"Angeli\u00a0P, Garcia-Tsao\u00a0G, Nadim\u00a0MK, Parikh\u00a0CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the international club of ascites (ICA) consensus document. J\u00a0Hepatol. 2019;71:811\u201322.","journal-title":"J Hepatol"},{"key":"2229_CR154","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli\u00a0P, Gines\u00a0P, Wong\u00a0F, Bernardi\u00a0M, Boyer\u00a0TD, Gerbes\u00a0A, et\u00a0al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites. Gut. 2015;64:531\u20137.","journal-title":"Gut"},{"key":"2229_CR155","doi-asserted-by":"publisher","first-page":"175628482211026","DOI":"10.1177\/17562848221102679","volume":"15","author":"C Bera","year":"2022","unstructured":"Bera\u00a0C, Wong\u00a0F. Management of hepatorenal syndrome in liver cirrhosis: a\u00a0recent update. Therap Adv Gastroenterol. 2022;15:17562848221102679.","journal-title":"Therap Adv Gastroenterol"},{"key":"2229_CR156","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/hep.29303","volume":"66","author":"R Amathieu","year":"2017","unstructured":"Amathieu\u00a0R, Al-Khafaji\u00a0A, Sileanu\u00a0FE, Foldes\u00a0E, DeSensi\u00a0R, Hilmi\u00a0I, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatology. 2017;66:1592\u2013600.","journal-title":"Hepatology"},{"issue":"4","key":"2229_CR157","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3350\/cmh.2016.0056","volume":"22","author":"F Wong","year":"2016","unstructured":"Wong\u00a0F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol. 2016;22(4):415\u201322.","journal-title":"Clin Mol Hepatol"},{"key":"2229_CR158","first-page":"253","volume":"62","author":"F Wong","year":"2016","unstructured":"Wong\u00a0F. Diagnosing and treating renal disease in cirrhotic patients. Minerva Gastroenterol Dietol. 2016;62:253\u201366.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2229_CR159","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/hep.25931","volume":"56","author":"YM Arabi","year":"2012","unstructured":"Arabi\u00a0YM, Dara\u00a0SI, Memish\u00a0Z, Al Abdulkareem\u00a0A, Tamim\u00a0HM, Al-Shirawi\u00a0N, et al. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. Hepatology. 2012;56:2305\u201315.","journal-title":"Hepatology"},{"key":"2229_CR160","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gutjnl-2011-301255","volume":"62","author":"CD Tsien","year":"2013","unstructured":"Tsien\u00a0CD, Rabie\u00a0R, Wong\u00a0F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131\u20137.","journal-title":"Gut"},{"key":"2229_CR161","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Martin-Llahi","year":"2008","unstructured":"Martin-Llahi\u00a0M, Pepin\u00a0MN, Guevara\u00a0M, Diaz\u00a0F, Torre\u00a0A, Monescillo\u00a0A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a\u00a0randomized study. Gastroenterology. 2008;134:1352\u20139.","journal-title":"Gastroenterology"},{"key":"2229_CR162","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","volume":"14","author":"C Alessandria","year":"2002","unstructured":"Alessandria\u00a0C, Venon\u00a0WD, Marzano\u00a0A, Barletti\u00a0C, Fadda\u00a0M, Rizzetto\u00a0M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14:1363\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR163","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/lt.24210","volume":"21","author":"E Rodriguez","year":"2015","unstructured":"Rodriguez\u00a0E, Henrique Pereira\u00a0G, Sola\u00a0E, Elia\u00a0C, Barreto\u00a0R, Pose\u00a0E, et\u00a0al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes. Liver Transpl. 2015;21:1347\u201354.","journal-title":"Liver Transpl"},{"key":"2229_CR164","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0168-8278(97)80428-X","volume":"26","author":"A Escorsell","year":"1997","unstructured":"Escorsell\u00a0A, Bandi\u00a0JC, Moitinho\u00a0E, Feu\u00a0F, Garcia-Pagan\u00a0JC, Bosch\u00a0J, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J\u00a0Hepatol. 1997;26:621\u20137.","journal-title":"J Hepatol"},{"key":"2229_CR165","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa2008290","volume":"384","author":"F Wong","year":"2021","unstructured":"Wong\u00a0F, Pappas\u00a0SC, Curry\u00a0MP, Reddy\u00a0KR, Rubin\u00a0RA, Porayko\u00a0MK, et\u00a0al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N\u00a0Engl J Med. 2021;384:818\u201328.","journal-title":"N Engl J Med"},{"key":"2229_CR166","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/hep.23893","volume":"52","author":"E Sola","year":"2010","unstructured":"Sola\u00a0E, Lens\u00a0S, Guevara\u00a0M, Martin-Llahi\u00a0M, Fagundes\u00a0C, Pereira\u00a0G, et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology. 2010;52:1783\u201390.","journal-title":"Hepatology"},{"key":"2229_CR167","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/hep.28396","volume":"63","author":"M Cavallin","year":"2016","unstructured":"Cavallin\u00a0M, Piano\u00a0S, Romano\u00a0A, Fasolato\u00a0S, Frigo\u00a0AC, Benetti\u00a0G, et\u00a0al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983\u201392.","journal-title":"Hepatology"},{"key":"2229_CR168","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/liv.13252","volume":"37","author":"A Choudhury","year":"2017","unstructured":"Choudhury\u00a0A, Kedarisetty\u00a0CK, Vashishtha\u00a0C, Saini\u00a0D, Kumar\u00a0S, Maiwall\u00a0R, et\u00a0al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2017;37:552\u201361.","journal-title":"Liver Int"},{"key":"2229_CR169","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cgh.2016.07.016","volume":"15","author":"F Wong","year":"2017","unstructured":"Wong\u00a0F, Pappas\u00a0SC, Boyer\u00a0TD, Sanyal\u00a0AJ, Bajaj\u00a0JS, Escalante\u00a0S, et\u00a0al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome. Clin Gastroenterol Hepatol. 2017;15:266\u2013272.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR170","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MEG.0000000000000537","volume":"28","author":"AZ Mattos","year":"2016","unstructured":"Mattos\u00a0AZ, Mattos\u00a0AA, Ribeiro\u00a0RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28:345\u201351.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR171","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/hep.30208","volume":"71","author":"V Arora","year":"2020","unstructured":"Arora\u00a0V, Maiwall\u00a0R, Rajan\u00a0V, Jindal\u00a0A, Muralikrishna Shasthry\u00a0S, Kumar\u00a0G, et\u00a0al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71:600\u201310.","journal-title":"Hepatology"},{"key":"2229_CR172","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/jhep.2002.34343","volume":"36","author":"C Duvoux","year":"2002","unstructured":"Duvoux\u00a0C, Zanditenas\u00a0D, Hezode\u00a0C, Chauvat\u00a0A, Monin\u00a0JL, Roudot-Thoraval\u00a0F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a\u00a0pilot study. Hepatology. 2002;36:374\u201380.","journal-title":"Hepatology"},{"key":"2229_CR173","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/hep.510280219","volume":"28","author":"M Guevara","year":"1998","unstructured":"Guevara\u00a0M, Gines\u00a0P, Bandi\u00a0JC, Gilabert\u00a0R, Sort\u00a0P, Jimenez\u00a0W, et\u00a0al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416\u201322.","journal-title":"Hepatology"},{"key":"2229_CR174","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/gut.47.2.288","volume":"47","author":"KA Brensing","year":"2000","unstructured":"Brensing\u00a0KA, Textor\u00a0J, Perz\u00a0J, Schiedermaier\u00a0P, Raab\u00a0P, Strunk\u00a0H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a\u00a0phase II study. Gut. 2000;47:288\u201395.","journal-title":"Gut"},{"key":"2229_CR175","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.20262","volume":"40","author":"F Wong","year":"2004","unstructured":"Wong\u00a0F, Pantea\u00a0L, Sniderman\u00a0K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55\u201364.","journal-title":"Hepatology"},{"key":"2229_CR176","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jhep.2013.06.014","volume":"59","author":"M Rossle","year":"2013","unstructured":"Rossle\u00a0M. TIPS: 25\u00a0years later. J\u00a0Hepatol. 2013;59:1081\u201393.","journal-title":"J Hepatol"},{"key":"2229_CR177","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.gastro.2011.12.056","volume":"142","author":"A Kribben","year":"2012","unstructured":"Kribben\u00a0A, Gerken\u00a0G, Haag\u00a0S, Herget-Rosenthal\u00a0S, Treichel\u00a0U, Betz\u00a0C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:782\u2013789.e3.","journal-title":"Gastroenterology"},{"key":"2229_CR178","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/hep.26185","volume":"57","author":"R Banares","year":"2013","unstructured":"Banares\u00a0R, Nevens\u00a0F, Larsen\u00a0FS, Jalan\u00a0R, Albillos\u00a0A, Dollinger\u00a0M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57:1153\u201362.","journal-title":"Hepatology"},{"key":"2229_CR179","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2215\/CJN.03610417","volume":"13","author":"AS Allegretti","year":"2018","unstructured":"Allegretti\u00a0AS, Parada\u00a0XV, Eneanya\u00a0ND, Gilligan\u00a0H, Xu\u00a0D, Zhao\u00a0S, et\u00a0al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol. 2018;13:16\u201325.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2229_CR180","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/cc11188","volume":"16","author":"MK Nadim","year":"2012","unstructured":"Nadim\u00a0MK, Kellum\u00a0JA, Davenport\u00a0A, Wong\u00a0F, Davis\u00a0C, Pannu\u00a0N, et\u00a0al. Hepatorenal syndrome: the 8th international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2012;16:R23.","journal-title":"Crit Care"},{"key":"2229_CR181","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","volume":"23","author":"W Zhang","year":"2019","unstructured":"Zhang\u00a0W, Bai\u00a0M, Yu\u00a0Y, Li\u00a0L, Zhao\u00a0L, Sun\u00a0S, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a\u00a0systematic review and meta-analysis. Crit Care. 2019;23:22.","journal-title":"Crit Care"},{"key":"2229_CR182","unstructured":"Eurotransplant. Euortransplant manual (C)\u2014version 6.3.. https:\/\/www.eurotransplant.org\/wp-content\/uploads\/2022\/10\/H5-ELAS-MELD-October-2022.pdf. Accessed 03.2022."},{"key":"2229_CR183","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","volume":"362","author":"JC Garcia-Pagan","year":"2010","unstructured":"Garcia-Pagan\u00a0JC, Caca\u00a0K, Bureau\u00a0C, Laleman\u00a0W, Appenrodt\u00a0B, Luca\u00a0A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N\u00a0Engl J Med. 2010;362:2370\u20139.","journal-title":"N Engl J Med"},{"key":"2229_CR184","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/hep.20386","volume":"40","author":"A Monescillo","year":"2004","unstructured":"Monescillo\u00a0A, Martinez-Lagares\u00a0F, Ruiz-del-Arbol\u00a0L, Sierra\u00a0A, Guevara\u00a0C, Jimenez\u00a0E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40:793\u2013801.","journal-title":"Hepatology"},{"key":"2229_CR185","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.gastro.2020.09.026","volume":"160","author":"O Nicoar\u0103-Farc\u0103u","year":"2021","unstructured":"Nicoar\u0103-Farc\u0103u\u00a0O, Han\u00a0G, Rudler\u00a0M, Angrisani\u00a0D, Monescillo\u00a0A, Torres\u00a0F, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a\u00a0meta-analysis of individual patient data. Gastroenterology. 2021;160:193\u2013205.e10.","journal-title":"Gastroenterology"},{"key":"2229_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100717","author":"A Escorsell","year":"2023","unstructured":"Escorsell\u00a0A, Garcia-Pag\u00e1n\u00a0JC, Alvarado-Tapia\u00a0E, Aracil\u00a0C, Masnou\u00a0H, Villanueva\u00a0C, et al. Preemptive TIPS for the treatment of bleeding from gastric fundal varices: results of a randomized-controlled trial. JHEP Rep. 2023; https:\/\/doi.org\/10.1016\/j.jhepr.2023.100717.","journal-title":"JHEP Rep"},{"key":"2229_CR187","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/hep.31913","volume":"74","author":"A Walter","year":"2021","unstructured":"Walter\u00a0A, Rudler\u00a0M, Olivas\u00a0P, Moga\u00a0L, Trepo\u00a0E, Robic\u00a0MA, et al. Combination of model for end-stage liver disease and lactate predicts death in patients treated with salvage transjugular Intrahepatic portosystemic shunt for refractory variceal bleeding. Hepatology. 2021;74:2085\u2013101.","journal-title":"Hepatology"},{"key":"2229_CR188","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert\u00a0M, Kovacs\u00a0G, Hoeper\u00a0MM, Badagliacca\u00a0R, Berger\u00a0RMF, Brida\u00a0M, et\u00a0al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart\u00a0J. 2022;43:3618\u2013731.","journal-title":"Eur Heart J"},{"key":"2229_CR189","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.dld.2016.10.011","volume":"49","author":"S Fagiuoli","year":"2017","unstructured":"Fagiuoli\u00a0S, Bruno\u00a0R, Debernardi Venon\u00a0W, Schepis\u00a0F, Vizzutti\u00a0F, Toniutto\u00a0P, et\u00a0al. Consensus conference on TIPS management: techniques, indications, contraindications. Dig Liver Dis. 2017;49:121\u201337.","journal-title":"Dig Liver Dis"},{"key":"2229_CR190","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.jhepr.2020.100122","volume":"2","author":"JC Garc\u00eda-Pag\u00e1n","year":"2020","unstructured":"Garc\u00eda-Pag\u00e1n\u00a0JC, Saffo\u00a0S, Mandorfer\u00a0M, Garcia-Tsao\u00a0G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep. 2020;2:100122.","journal-title":"JHEP Rep"},{"key":"2229_CR191","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jhep.2020.04.024","volume":"73","author":"J Trebicka","year":"2020","unstructured":"Trebicka\u00a0J, Gu\u00a0W, Ibanez-Samaniego\u00a0L, Hernandez-Gea\u00a0V, Pitarch\u00a0C, Garcia\u00a0E, et al. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. J\u00a0Hepatol. 2020;73:1082\u201391.","journal-title":"J Hepatol"},{"key":"2229_CR192","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5152\/dir.2016.15601","volume":"23","author":"AN Tavare","year":"2017","unstructured":"Tavare\u00a0AN, Wigham\u00a0A, Hadjivassilou\u00a0A, Alvi\u00a0A, Papadopoulou\u00a0A, Goode\u00a0A, et al. Use of transabdominal ultrasound-guided transjugular portal vein puncture on radiation dose in transjugular intrahepatic portosystemic shunt formation. Diagn Interv Radiol. 2017;23:206\u201310.","journal-title":"Diagn Interv Radiol"},{"key":"2229_CR193","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s001170050127","volume":"36","author":"T Roeren","year":"1996","unstructured":"Roeren\u00a0T, Richter\u00a0GM, Limberg\u00a0B, Jacoby\u00a0IR, Kauffmann\u00a0GW. Ultrasound guided puncture of the portal vein in transjugular intrahepatic portasystemic stent shunt (TIPSS). Radiologe. 1996;36:677\u201382.","journal-title":"Radiologe"},{"key":"2229_CR194","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/1754-9485.13288","volume":"66","author":"A Lamanna","year":"2022","unstructured":"Lamanna\u00a0A, Mitreski\u00a0G, Maingard\u00a0J, Owen\u00a0A, Schelleman\u00a0T, Goodwin\u00a0M, et al. Ultrasound-guided portal vein puncture during transjugular intrahepatic portosystemic shunt: technique and experience of a\u00a0quaternary liver transplant hospital. J\u00a0Med Imaging Radiat Oncol. 2022;66:60\u20137.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2229_CR195","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5334\/jbr-btr.398","volume":"96","author":"A Van Holsbeeck","year":"2013","unstructured":"Van Holsbeeck\u00a0A, Thijs\u00a0M, Bielen\u00a0D, Heye\u00a0S, Maleux\u00a0G. Sonographic evaluation of transjugular intrahepatic portosystemic shunt. J\u00a0Belge Radiol. 2013;96:275\u201381.","journal-title":"J Belge Radiol"},{"key":"2229_CR196","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.diii.2019.01.004","volume":"100","author":"A David","year":"2019","unstructured":"David\u00a0A, Liberge\u00a0R, Meyer\u00a0J, Morla\u00a0O, Leaute\u00a0F, Archambeaud\u00a0I, et\u00a0al. Ultrasonographic guidance for portal vein access during transjugular intrahepatic portosystemic shunt (TIPS) placement. Diagn Interv Imaging. 2019;100:445\u201353.","journal-title":"Diagn Interv Imaging"},{"key":"2229_CR197","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1148\/radiol.2512080423","volume":"251","author":"R Adamus","year":"2009","unstructured":"Adamus\u00a0R, Pfister\u00a0M, Loose\u00a0RW. Enhancing transjugular intrahepatic portosystemic shunt puncture by using three-dimensional path planning based on the back projection of two two-dimensional portographs. Radiology. 2009;251:543\u20137.","journal-title":"Radiology"},{"key":"2229_CR198","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1076-6332(99)80487-5","volume":"6","author":"L Yang","year":"1999","unstructured":"Yang\u00a0L, Bettmann\u00a0MA. Identification of the portal vein: wedge hepatic venography with CO2 or iodinated contrast medium. Acad Radiol. 1999;6:89\u201393.","journal-title":"Acad Radiol"},{"key":"2229_CR199","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00270-001-0096-5","volume":"25","author":"A Krajina","year":"2002","unstructured":"Krajina\u00a0A, Lojik\u00a0M, Chovanec\u00a0V, Raupach\u00a0J, Hulek\u00a0P. Wedged hepatic venography for targeting the portal vein during TIPS: comparison of carbon dioxide and iodinated contrast agents. Cardiovasc Intervent Radiol. 2002;25:171\u20135.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2229_CR200","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2214\/AJR.12.9060","volume":"199","author":"M Darcy","year":"2012","unstructured":"Darcy\u00a0M. Evaluation and management of transjugular intrahepatic portosystemic shunts. AJR Am J Roentgenol. 2012;199:730\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"2229_CR201","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","volume":"156","author":"NM Intagliata","year":"2019","unstructured":"Intagliata\u00a0NM, Caldwell\u00a0SH, Tripodi\u00a0A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156:1582\u20131599.e1.","journal-title":"Gastroenterology"},{"key":"2229_CR202","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J\u00a0Hepatol. 2016;64:179\u2013202.","journal-title":"J Hepatol"},{"issue":"6","key":"2229_CR203","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","volume":"75","author":"F Turon","year":"2021","unstructured":"Turon\u00a0F, Driever\u00a0EG, Baiges\u00a0A, Cerda\u00a0E, Garcia-Criado\u00a0A, Gilabert\u00a0R, et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J\u00a0Hepatol. 2021;75(6):1367\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.020.","journal-title":"J Hepatol"},{"key":"2229_CR204","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4254\/wjh.v9.i3.139","volume":"9","author":"JG Stine","year":"2017","unstructured":"Stine\u00a0JG, Argo\u00a0CK, Pelletier\u00a0SJ, Maluf\u00a0DG, Caldwell\u00a0SH, Northup\u00a0PG. Advanced non-alcoholic steatohepatitis cirrhosis: a high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017;9:139\u201346.","journal-title":"World J Hepatol"},{"issue":"1","key":"2229_CR205","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hep.31646","volume":"73","author":"PG Northup","year":"2021","unstructured":"Northup\u00a0PG, Garcia-Pagan\u00a0JC, Garcia-Tsao\u00a0G, Intagliata\u00a0NM, Superina\u00a0RA, Roberts\u00a0LN, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;73(1):366\u2013413. https:\/\/doi.org\/10.1002\/hep.31646.","journal-title":"Hepatology"},{"key":"2229_CR206","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1097\/00007890-200005150-00023","volume":"69","author":"MA Yerdel","year":"2000","unstructured":"Yerdel\u00a0MA, Gunson\u00a0B, Mirza\u00a0D, Karayalcin\u00a0K, Olliff\u00a0S, Buckels\u00a0J, et\u00a0al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation. 2000;69:1873\u201381.","journal-title":"Transplantation"},{"key":"2229_CR207","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-0040-1722260","volume":"41","author":"MJ Stotts","year":"2021","unstructured":"Stotts\u00a0MJ, Wentworth\u00a0BJ, Northup\u00a0PG. Management of portal vein thrombosis in cirrhosis. Semin Liver Dis. 2021;41:79\u201386.","journal-title":"Semin Liver Dis"},{"key":"2229_CR208","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.dld.2016.11.013","volume":"49","author":"C Margini","year":"2017","unstructured":"Margini\u00a0C, Berzigotti\u00a0A. Portal vein thrombosis: the role of imaging in the clinical setting. Dig Liver Dis. 2017;49:113\u201320.","journal-title":"Dig Liver Dis"},{"key":"2229_CR209","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2016.08.033","volume":"151","author":"SK Sarin","year":"2016","unstructured":"Sarin\u00a0SK, Philips\u00a0CA, Kamath\u00a0PS, Choudhury\u00a0A, Maruyama\u00a0H, Nery\u00a0FG, et\u00a0al. Toward a\u00a0comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology. 2016;151:574\u2013577.e3.","journal-title":"Gastroenterology"},{"key":"2229_CR210","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.27546","volume":"61","author":"F Nery","year":"2015","unstructured":"Nery\u00a0F, Chevret\u00a0S, Condat\u00a0B, de Raucourt\u00a0E, Boudaoud\u00a0L, Rautou\u00a0PE, et\u00a0al. Causes and consequences of portal vein thrombosis in 1,243\u00a0patients with cirrhosis: results of a\u00a0longitudinal study. Hepatology. 2015;61:660\u20137.","journal-title":"Hepatology"},{"key":"2229_CR211","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/tri.13353","volume":"31","author":"A Zanetto","year":"2018","unstructured":"Zanetto\u00a0A, Rodriguez-Kastro\u00a0KI, Germani\u00a0G, Ferrarese\u00a0A, Cillo\u00a0U, Burra\u00a0P, et al. Mortality in liver transplant recipients with portal vein thrombosis\u2014an updated meta-analysis. Transpl Int. 2018;31:1318\u201329.","journal-title":"Transpl Int"},{"key":"2229_CR212","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.cgh.2017.10.016","volume":"16","author":"V La Mura","year":"2018","unstructured":"La Mura\u00a0V, Braham\u00a0S, Tosetti\u00a0G, Branchi\u00a0F, Bitto\u00a0N, Moia\u00a0M, et\u00a0al. Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2018;16:1146\u20131152.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2229_CR213","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","volume":"114","author":"I Pettinari","year":"2019","unstructured":"Pettinari\u00a0I, Vukotic\u00a0R, Stefanescu\u00a0H, Pecorelli\u00a0A, Morelli\u00a0M, Grigoras\u00a0C, et\u00a0al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114(2):258\u201366. https:\/\/doi.org\/10.1038\/s41395-018-0421-0.","journal-title":"Am J Gastroenterol"},{"key":"2229_CR214","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","volume":"153","author":"L Loffredo","year":"2017","unstructured":"Loffredo\u00a0L, Pastori\u00a0D, Farcomeni\u00a0A, Violi\u00a0F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153:480\u2013487.e1.","journal-title":"Gastroenterology"},{"key":"2229_CR215","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1055\/s-0040-1722192","volume":"121","author":"E Valeriani","year":"2021","unstructured":"Valeriani\u00a0E, Di Nisio\u00a0M, Riva\u00a0N, Cohen\u00a0O, Porreca\u00a0E, Senzolo\u00a0M, et al. Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Thromb Haemost. 2021;121:867\u201376.","journal-title":"Thromb Haemost"},{"key":"2229_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.02.023","author":"A Guerrero","year":"2023","unstructured":"Guerrero\u00a0A, Campo\u00a0LD, Piscaglia\u00a0F, Scheiner\u00a0B, Han\u00a0G, Violi\u00a0F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis. J\u00a0Hepatol. 2023; https:\/\/doi.org\/10.1016\/j.jhep.2023.02.023.","journal-title":"J Hepatol"},{"key":"2229_CR217","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/ajg.2012.313","volume":"107","author":"L Amitrano","year":"2012","unstructured":"Amitrano\u00a0L, Guardascione\u00a0MA, Manguso\u00a0F, Bennato\u00a0R, Bove\u00a0A, DeNucci\u00a0C, et al. The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors. Am J Gastroenterol. 2012;107:1872\u20138.","journal-title":"Am J Gastroenterol"},{"key":"2229_CR218","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","volume":"75","author":"M Senzolo","year":"2021","unstructured":"Senzolo\u00a0M, Garcia-Tsao\u00a0G, Garcia-Pagan\u00a0JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J\u00a0Hepatol. 2021;75:442\u201353.","journal-title":"J Hepatol"},{"key":"2229_CR219","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/j.1538-7836.2012.04824.x","volume":"10","author":"M Senzolo","year":"2012","unstructured":"Senzolo\u00a0M, Rodriguez-Castro\u00a0KI, Rossetto\u00a0V, Radu\u00a0C, Gavasso\u00a0S, Carraro\u00a0P, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J\u00a0Thromb Haemost. 2012;10:1823\u20139.","journal-title":"J Thromb Haemost"},{"key":"2229_CR220","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/liv.14992","volume":"41","author":"G Semmler","year":"2021","unstructured":"Semmler\u00a0G, Pomej\u00a0K, Bauer\u00a0DJM, Balcar\u00a0L, Simbrunner\u00a0B, Binter\u00a0T, et\u00a0al. Safety of direct oral anticoagulants in patients with advanced liver disease. Liver Int. 2021;41:2159\u201370.","journal-title":"Liver Int"},{"key":"2229_CR221","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/liv.13285","volume":"37","author":"A De Gottardi","year":"2017","unstructured":"De Gottardi\u00a0A, Trebicka\u00a0J, Klinger\u00a0C, Plessier\u00a0A, Seijo\u00a0S, Terziroli\u00a0B, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694\u20139.","journal-title":"Liver Int"},{"issue":"7","key":"2229_CR222","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","volume":"19","author":"JF Mort","year":"2021","unstructured":"Mort\u00a0JF, Davis\u00a0JPE, Mahoro\u00a0G, Stotts\u00a0MJ, Intagliata\u00a0NM, Northup\u00a0PG. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol. 2021;19(7):1436\u201342. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.007.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR223","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.coph.2021.07.006","volume":"60","author":"C De Maria","year":"2021","unstructured":"De Maria\u00a0C, Galante\u00a0A, Fasoli\u00a0A, De Gottardi\u00a0A. When and how to use direct oral anticoagulants in patients with advanced chronic liver disease? Curr Opin Pharmacol. 2021;60:111\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"2229_CR224","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","volume":"31","author":"KI Rodriguez-Castro","year":"2019","unstructured":"Rodriguez-Castro\u00a0KI, Vitale\u00a0A, Fadin\u00a0M, Shalaby\u00a0S, Zerbinati\u00a0P, Sartori\u00a0MT, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol. 2019;31:34\u201342.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR225","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","volume":"115","author":"DA Simonetto","year":"2020","unstructured":"Simonetto\u00a0DA, Singal\u00a0AK, Garcia-Tsao\u00a0G, Caldwell\u00a0SH, Ahn\u00a0J, Kamath\u00a0PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol. 2020;115:18\u201340.","journal-title":"Am J Gastroenterol"},{"key":"2229_CR226","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","volume":"10","author":"MG Delgado","year":"2012","unstructured":"Delgado\u00a0MG, Seijo\u00a0S, Yepes\u00a0I, Achecar\u00a0L, Catalina\u00a0MV, Garcia-Criado\u00a0A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10:776\u201383.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2229_CR227","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis\u00a0R, Baveno\u00a0VIF. Expanding consensus in portal hypertension: report of the Baveno\u00a0VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J\u00a0Hepatol. 2015;63:743\u201352.","journal-title":"J Hepatol"},{"key":"2229_CR228","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/MEG.0000000000001522","volume":"32","author":"S Ponthus","year":"2020","unstructured":"Ponthus\u00a0S, Spahr\u00a0L, Casini\u00a0A, Berney\u00a0T, Frossard\u00a0JL, Majno\u00a0P, et\u00a0al. Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: a retrospective study. Eur J Gastroenterol Hepatol. 2020;32:395\u2013400.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR229","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/liv.13728","volume":"38","author":"M Bianchini","year":"2018","unstructured":"Bianchini\u00a0M, Cavani\u00a0G, Bonaccorso\u00a0A, Turco\u00a0L, Vizzutti\u00a0F, Sartini\u00a0A, et al. Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. Liver Int. 2018;38:1253\u201362.","journal-title":"Liver Int"},{"key":"2229_CR230","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/MEG.0000000000001061","volume":"30","author":"M Guillaume","year":"2018","unstructured":"Guillaume\u00a0M, Christol\u00a0C, Plessier\u00a0A, Corbic\u00a0M, Peron\u00a0JM, Sommet\u00a0A, et\u00a0al. Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation. Eur J Gastroenterol Hepatol. 2018;30:563\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR231","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.dld.2019.06.019","volume":"52","author":"E Duenas","year":"2020","unstructured":"Duenas\u00a0E, Cachero\u00a0A, Amador\u00a0A, Rota\u00a0R, Salord\u00a0S, Gornals\u00a0J, et\u00a0al. Ulcer bleeding after band ligation of esophageal varices: risk factors and prognosis. Dig Liver Dis. 2020;52:79\u201383.","journal-title":"Dig Liver Dis"},{"key":"2229_CR232","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/apt.15044","volume":"49","author":"SG Rodrigues","year":"2019","unstructured":"Rodrigues\u00a0SG, Sixt\u00a0S, Abraldes\u00a0JG, De Gottardi\u00a0A, Klinger\u00a0C, Bosch\u00a0J, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019;49:20\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"2229_CR233","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1148\/radiol.15141252","volume":"276","author":"X Luo","year":"2015","unstructured":"Luo\u00a0X, Wang\u00a0Z, Tsauo\u00a0J, Zhou\u00a0B, Zhang\u00a0H, Li\u00a0X. Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology. 2015;276:286\u201393.","journal-title":"Radiology"},{"key":"2229_CR234","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1148\/radiol.2015150369","volume":"279","author":"Z Wang","year":"2016","unstructured":"Wang\u00a0Z, Jiang\u00a0MS, Zhang\u00a0HL, Weng\u00a0NN, Luo\u00a0XF, Li\u00a0X, et al. Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial. Radiology. 2016;279:943\u201351.","journal-title":"Radiology"},{"key":"2229_CR235","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.dld.2016.12.019","volume":"49","author":"A Zanetto","year":"2017","unstructured":"Zanetto\u00a0A, Senzolo\u00a0M, Vitale\u00a0A, Cillo\u00a0U, Radu\u00a0C, Sartorello\u00a0F, et\u00a0al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis. 2017;49:440\u20135.","journal-title":"Dig Liver Dis"},{"key":"2229_CR236","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J\u00a0Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"2229_CR237","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1055\/s-0043-119356","volume":"39","author":"C Serra","year":"2018","unstructured":"Serra\u00a0C, Grasso\u00a0V, Conti\u00a0F, Felicani\u00a0C, Mazzotta\u00a0E, Lenzi\u00a0M, et al. A new two-dimensional shear wave elastography for noninvasive assessment of liver fibrosis in healthy subjects and in patients with chronic liver disease. Ultraschall Med. 2018;39:432\u20139.","journal-title":"Ultraschall Med"},{"key":"2229_CR238","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/liv.12760","volume":"35","author":"KJ Fagan","year":"2015","unstructured":"Fagan\u00a0KJ, Pretorius\u00a0CJ, Horsfall\u00a0LU, Irvine\u00a0KM, Wilgen\u00a0U, Choi\u00a0K, et\u00a0al. ELF score \u3009\/=9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver Int. 2015;35:1673\u201381.","journal-title":"Liver Int"},{"key":"2229_CR239","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/liv.12896","volume":"36","author":"KM Irvine","year":"2016","unstructured":"Irvine\u00a0KM, Wockner\u00a0LF, Shanker\u00a0M, Fagan\u00a0KJ, Horsfall\u00a0LU, Fletcher\u00a0LM, et\u00a0al. The enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int. 2016;36:370\u20137.","journal-title":"Liver Int"},{"key":"2229_CR240","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1055\/a-0965-0745","volume":"41","author":"H Stefanescu","year":"2020","unstructured":"Stefanescu\u00a0H, Rusu\u00a0C, Lupsor-Platon\u00a0M, Nicoara Farcau\u00a0O, Fischer\u00a0P, Grigoras\u00a0C, et al. Liver stiffness assessed by ultrasound shear wave elastography from general electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease. Ultraschall Med. 2020;41:526\u201333.","journal-title":"Ultraschall Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02229-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02229-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02229-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T21:21:30Z","timestamp":1688505690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02229-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":240,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02229-w","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Mandorfer served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Albireo, Collective Acumen, Gilead, Takeda, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. E.\u00a0Aigner served as a\u00a0speaker and\/or consultant and\/or advisory board member for Gilead, Sanofi-Genzyme, Takeda, Advanz Pharma, Roche, Novartis. B.\u00a0Scheiner received travel support fromm AbbVie, Ipsen and Gilead. M.\u00a0Gschwantler received grants from AbbVie, Gilead, and MSD; speaking honoraria\/advisory board fees from AbbVie, Gilead, MSD, Janssen, BMS, Roche, Intercept, Alnylam, Norgine, AstraZeneca, Falk, Gebro Pharma and Shionogi. M.\u00a0Jachs served as a\u00a0speaker and\/or consultant for Gilead and received travel support from Gilead. S.\u00a0Hametner-Schreil served as speaker and\/or advisory board member for AbbVie, Gilead, Roche and MSD. M.\u00a0Peck-Radosavljevic has served as an investigator for AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Exelixis, Eisai, Gilead, Lilly, Ipsen, Novartis, and Roche. He has served as speaker or adviser for AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Gilead, Ipsen, Lilly, MSD, and Roche. He received grant support from Bayer and Gilead, and he served in data and safety monitoring boards for BMS, Boehringer Ingelheim, Lilly-Imclonse and ONEXO. P.\u00a0Schwabl served as constultant for PharmaIN. R.\u00a0Stauber served as a\u00a0speaker for Boston Scientific and Medtronic. S.\u00a0Reiter received speakers\u2019 honoraria from Intercept Pharma Austria as well as travel support from AbbVie and Gilead. M.\u00a0Trauner received grant support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and UltraGenyx, honoraria for consulting from Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, and Shire, speaker fees from Bristol-Myers Squibb, Falk, Gilead, Intercept, and MSD, as well as travel support from AbbVie, Falk, Gilead, Intercept and Jannsen. V.\u00a0Stadlbauer received speaker\u2019s honoraria and travel support from Merz Therapeutics, Albireo, Sanofi. T.\u00a0Reiberger served as a\u00a0speaker and\/or consultant and\/or advisory board member speaking honoraria from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Roche, Siemens, and W. L.\u00a0Gore & Associates and received travel support from AbbVie, Boehringer-Ingelheim, Gilead, and Roche as well as grants\/research support from AbbVie, Boehringer-Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens, and W.\u00a0L. Gore & Associates. M.\u00a0Cejna, A.\u00a0Ferlitsch, C.\u00a0Datz, T.\u00a0Gr\u00e4ter, I.\u00a0Graziadei, H.\u00a0Hofer, A.\u00a0Loizides, A.\u00a0Maieron, F.\u00a0Rainer, , G.\u00a0Semmler, L.\u00a0Reider, M.\u00a0Schoder, R.\u00a0Sch\u00f6fl, E.\u00a0Tatscher, A.\u00a0Ziachehabi, H.\u00a0Zoller and P.\u00a0Fickert declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}